BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33193346)

  • 1. Protective Intranasal Immunization Against Influenza Virus in Infant Mice Is Dependent on IL-6.
    Bonney EA; Krebs K; Kim J; Prakash K; Torrance BL; Haynes L; Rincon M
    Front Immunol; 2020; 11():568978. PubMed ID: 33193346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD47 Plays a Role as a Negative Regulator in Inducing Protective Immune Responses to Vaccination against Influenza Virus.
    Lee YT; Ko EJ; Lee Y; Lee YN; Bian Z; Liu Y; Kang SM
    J Virol; 2016 Aug; 90(15):6746-6758. PubMed ID: 27194758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
    Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
    J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
    Ji X; Ren Z; Xu N; Meng L; Yu Z; Feng N; Sang X; Li S; Li Y; Wang T; Zhao Y; Wang H; Zheng X; Jin H; Li N; Yang S; Cao J; Liu W; Gao Y; Xia X
    Viruses; 2016 Apr; 8(4):115. PubMed ID: 27110810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus.
    Kayamuro H; Yoshioka Y; Abe Y; Arita S; Katayama K; Nomura T; Yoshikawa T; Kubota-Koketsu R; Ikuta K; Okamoto S; Mori Y; Kunisawa J; Kiyono H; Itoh N; Nagano K; Kamada H; Tsutsumi Y; Tsunoda S
    J Virol; 2010 Dec; 84(24):12703-12. PubMed ID: 20881038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal Introduction of Fc-Fused Interleukin-7 Provides Long-Lasting Prophylaxis against Lethal Influenza Virus Infection.
    Kang MC; Choi DH; Choi YW; Park SJ; Namkoong H; Park KS; Ahn SS; Surh CD; Yoon SW; Kim DJ; Choi JA; Park Y; Sung YC; Lee SW
    J Virol; 2015 Dec; 90(5):2273-84. PubMed ID: 26656713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection.
    Wang BZ; Xu R; Quan FS; Kang SM; Wang L; Compans RW
    PLoS One; 2010 Nov; 5(11):e13972. PubMed ID: 21124769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines.
    Dong W; Bhide Y; Sicca F; Meijerhof T; Guilfoyle K; Engelhardt OG; Boon L; de Haan CAM; Carnell G; Temperton N; de Vries-Idema J; Kelvin D; Huckriede A
    Front Immunol; 2018; 9():2312. PubMed ID: 30356772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
    Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
    mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against lethal influenza virus encephalitis by intranasally primed CD8+ memory T cells.
    Stevenson PG; Hawke S; Bangham CR
    J Immunol; 1996 Oct; 157(7):3065-73. PubMed ID: 8816416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ginseng and Salviae herbs play a role as immune activators and modulate immune responses during influenza virus infection.
    Quan FS; Compans RW; Cho YK; Kang SM
    Vaccine; 2007 Jan; 25(2):272-82. PubMed ID: 16945454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective cellular and mucosal immune responses following nasal administration of a whole gamma-irradiated influenza A (subtype H1N1) vaccine adjuvanted with interleukin-28B in a mouse model.
    Sabbaghi A; Zargar M; Zolfaghari MR; Motamedi-Sedeh F; Ghaemi A
    Arch Virol; 2021 Feb; 166(2):545-557. PubMed ID: 33409549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory vaccination of mice against influenza virus: dissection of T- and B-cell priming functions.
    Coleclough C; Sealy R; Surman S; Marshall DR; Hurwitz JL
    Scand J Immunol; 2005 Jul; 62 Suppl 1():73-83. PubMed ID: 15953188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCR2 Regulates Vaccine-Induced Mucosal T-Cell Memory to Influenza A Virus.
    Lee W; Kingstad-Bakke B; Kedl RM; Kawaoka Y; Suresh M
    J Virol; 2021 Jul; 95(15):e0053021. PubMed ID: 33952647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local IL-4 expression in the lung reduces pulmonary influenza-virus-specific secondary cytotoxic T cell responses.
    Bot A; Holz A; Christen U; Wolfe T; Temann A; Flavell R; von Herrath M
    Virology; 2000 Mar; 269(1):66-77. PubMed ID: 10725199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge.
    Galarza JM; Latham T; Cupo A
    Viral Immunol; 2005; 18(2):365-72. PubMed ID: 16035948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A detrimental effect of interleukin-10 on protective pulmonary humoral immunity during primary influenza A virus infection.
    Sun K; Torres L; Metzger DW
    J Virol; 2010 May; 84(10):5007-14. PubMed ID: 20200252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant H5 hemagglutinin adjuvanted with nanoemulsion protects ferrets against pathogenic avian influenza virus challenge.
    Wang SH; Smith D; Cao Z; Chen J; Acosta H; Chichester JA; Yusibov V; Streatfield SJ; Fattom A; Baker JR
    Vaccine; 2019 Mar; 37(12):1591-1600. PubMed ID: 30795941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient vagina-to-lower respiratory tract immune trafficking in a murine model of influenza A virus infection.
    Garulli B; Meola M; Stillitano MG; Kawaoka Y; Castrucci MR
    Virology; 2007 May; 361(2):274-82. PubMed ID: 17222437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.